A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers

Inclusion Criteria:

1. Non-smoking adult healthy male and female, aged 18 to 65 years (inclusive), at the time of consent with a body mass index (BMI) between 18.0 and 32.0 kg/m2 (inclusive), at Screening.
2. Healthy as determined by medical history, physical examination, vital signs, clinical laboratory safety tests, ECG, and chest X-ray

Exclusion Criteria:

1. Active bacterial, viral, fungal infection or known inflammatory process, infection or antibiotic treatment
2. Laboratory test results outside the local reference range and deemed clinically significant
3. History of chronic medications, immunosuppressant or steroids
4. History of malignant neoplasm
5. History of relevant atopy
6. History of hypersensitivity to biologic agents or any of the excipients in the formulation.
7. Excessive xanthine consumption
8. History of drug or alcohol addiction or dependence within 1 year
9. Positive of a tuberculosis test or a history of tuberculosis
10. Abnormal blood pressure and/or ECG parameters
11. Any prescribed medications within 28 days or nonprescription drugs within 7 days
12. Previously received aldesleukin or any other IL-2 derivative